Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 7201 AL 7215

Presenile dementia: a case of Hashimoto's encephalopathy

Chong CS, Leung JL, Wong IH, Ng PW, Miao MY.

East Asian Arch Psychiatry. 2011 Mar;21(1):32-6.

Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development

Ehrnhoefer DE, Wong BK, Hayden MR.

Nat Rev Drug Discov. 2011 Oct 21;10(11):853-67. doi: 10.1038/nrd3556.

Epigenetic treatment of neurological disease

Gray SG.

Epigenomics. 2011 Aug;3(4):431-50. doi: 10.2217/epi.11.67.

The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease

da Rocha MD, Viegas FP, Campos HC, Nicastro PC, Fossaluzza PC, Fraga CA, Barreiro EJ, Viegas C Jr.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):251-70. doi: 10.2174/187152711794480429.

Implication of oncogenic signaling pathways as a treatment strategy for neurodegenerative disorders - contemporary approaches

Sieradzki A, Yendluri BB, Palacios HH, Parvathaneni K, Reddy VP, Obrenovich ME, Gąsiorowski K, Leszek J, Aliev G.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):175-83. doi: 10.2174/187152711794480410.

Mitophagy in neurodegeneration: an opportunity for therapy?

Santos RX, Correia SC, Carvalho C, Cardoso S, Santos MS, Moreira PI.

Curr Drug Targets. 2011 Jun;12(6):790-9. doi: 10.2174/138945011795528813.

Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine

Flood DG, Marek GJ, Williams M.

Biochem Pharmacol. 2011 Jun 15;81(12):1422-34. doi: 10.1016/j.bcp.2011.01.021. Epub 2011 Feb 3.

Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim

Weinreb O, Mandel S, Bar-Am O, Amit T.

J Neural Transm (Vienna). 2011 Mar;118(3):479-92. doi: 10.1007/s00702-011-0597-6. Epub 2011 Mar 1.

Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases

Kawamata J, Shimohama S.

J Alzheimers Dis. 2011;24 Suppl 2:95-109. doi: 10.3233/JAD-2011-110173.

Metal ions, Alzheimer's disease and chelation therapy

Budimir A.

Acta Pharm. 2011 Mar;61(1):1-14. doi: 10.2478/v10007-011-0006-6.

Steroid-responsive encephalopathy subsequently associated with Alzheimer's disease pathology: a case series

Mateen FJ, Josephs KA, Parisi JE, Drubach DA, Caselli RJ, Kantarci K, Jack C Jr, Boeve BF.

Neurocase. 2012 Feb;18(1):1-12. doi: 10.1080/13554794.2010.547503. Epub 2011 Jun 30.

Therapeutic intervention at cellular quality control systems in Alzheimer's and Parkinson's diseases

Arduino DM, Esteves AR, Silva DF, Martins-Branco D, Santos D, Pimentel DF, Cardoso SM.

Curr Pharm Des. 2011;17(31):3446-59. doi: 10.2174/138161211798072481.

Targeting HDACs: a promising therapy for Alzheimer's disease

Xu K, Dai XL, Huang HC, Jiang ZF.

Oxid Med Cell Longev. 2011;2011:143269. doi: 10.1155/2011/143269. Epub 2011 Sep 20.

Multimodal drugs and their future for Alzheimer's and Parkinson's disease

Van der Schyf CJ, Geldenhuys WJ.

Int Rev Neurobiol. 2011;100:107-25. doi: 10.1016/B978-0-12-386467-3.00006-6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias